• Precision BioSciences secured a late-breaking oral slot at AASLD’s Liver Meeting 2026 for its PBGENE-HBV clinical program.
• Results have not been presented yet; data are scheduled for Nov. 8, 2026, in Denver.
• The abstract reports durable loss of a key viral RNA signal in both HBeAg-positive and HBeAg-negative patients.
• The readout supports a potential path toward a functional cure strategy, a key de-risking milestone for the program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Precision BioSciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610080701BIZWIRE_USPR_____20261008_BW153055) on October 08, 2026, and is solely responsible for the information contained therein.